Paired vagus nerve stimulation (VNS) for Tinnitus: What Does the Evidence Show?
Neuromodulation
Current evidence
A promising pilot, then silence — the sponsor took the technology to stroke rehab instead.
Evidence strength: Limited (2/5) · Tier 3 — experimental/emerging · Evidence independence: Primarily sponsor-supported.
An implanted vagus nerve stimulator delivering pulses precisely paired with tones, intended to drive targeted auditory-cortex plasticity (MicroTransponder Serenity system).
Did tinnitus loudness improve?
None shown. No verified loudness-percept reduction data.
Did tinnitus distress improve?
Limited. Pilot RCT: 50% meaningful THI improvement vs 28% control at 6 weeks, concentrated in tonal, non-blast tinnitus.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
How strong is the evidence?
A single positive pilot with no follow-through: 2/5, dormant.
Has the result been independently replicated?
None yet.
What are the limitations?
- Invasive
- No development since ~2017
- Pilot-scale evidence only
Conflicts of interest: Industry-sponsored pilot.
What should patients know about safety?
Safety evidence: Limited. Requires surgery; VNS implant risks.
Is it available?
Regulatory status: Investigational (program dormant). Never authorized for tinnitus. The paired-VNS platform received FDA PMA approval as Vivistim (P210007, approved 2021-08-27) — for stroke upper-limb rehabilitation; the PMA applicant of record is now Mobia Medical, Inc. (successor to MicroTransponder).
Availability: Not available for tinnitus · Europe: Not available · Cost (approx.): N/A
What the studies found
Vagus nerve stimulation paired with tones: randomized double-blind pilot
Tyler R, et al. · Scientific Reports · 2017 · N=30 · Randomized double-blind controlled pilot (implanted VNS)
At 6 weeks, 50% of paired-VNS participants had clinically meaningful THI improvement vs 28% of controls — a difference NOT statistically significant in the full cohort; benefit concentrated in the tonal, non-blast-induced subgroup.
The sponsor (MicroTransponder) later pivoted its paired-VNS platform to stroke rehabilitation (Vivistim, FDA PMA 2021); no tinnitus development since.
Related treatments
- Auricle bisensory stimulation (Susan Shore device) — The only treatment with rigorous randomized evidence of making tinnitus quieter — still stuck in the lab.
- Lenire (bimodal tongue stimulation) — Pairs sound with mild tongue stimulation — the first and only device of its type the FDA has authorized for…
- Neosensory Duo (wristband bimodal) — A consumer wristband borrowing the bimodal idea — sold on one small company-run study.
- Acoustic coordinated reset (Desyncra) — A elegant theory whose confirmatory trial came back empty.
- Transcutaneous auricular VNS (taVNS) — Non-surgical vagus nerve stimulation via an ear clip — small pilots so far, with the largest trial ever now…
Evidence last reviewed: 2026-09-03 · Evidence included through: 2026-09-03 · Confidence: moderate. Open the interactive evidence profile.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.